NCT07793773Not yet recruiting
Disease Impact and Its Correlation With Disease Activity in Psoriatic Arthritis
Assessment of Disease Impact in Patients With Psoriatic Arthritis and Its Correlation With Disease Activity
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder that causes joint pain, stiffness, skin lesions, and functional disability, significantly affecting patients' quality of life. Patient-reported outcome measures (PROMs) provide essential insights into the impact of disease from the patient's perspective. The Psoriatic Arthritis Impact of Disease-12 (PsAID-12) questionnaire is a validated tool designed to evaluate 12 physical and psychological aspects of disease burden. The main purpose of this cross-sectional study is to evaluate disease impact using the Arabic version of the PsAID-12 questionnaire and to investigate how disease impact correlates with clinical disease activity measured by the Disease Activity in Psoriatic Arthritis (DAPSA) score in adult patients with PsA. Participants will undergo routine clinical and rheumatological evaluations, including joint examinations (tender and swollen joint counts), laboratory tests (complete blood count, inflammatory markers such as ESR and CRP, liver and kidney function tests, and lipid profile), and plain radiography of affected joints (hands, feet, and sacroiliac joints). Patients will also complete the Arabic PsAID-12 questionnaire and patient global and pain assessments. All assessments will take place during a single evaluation visit at Assiut University Hospital.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 26 Aug 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07793773
What you commit to
- Study type: Observational
- Planned participants: 80
- From 1 Oct 2026 to the primary completion date, 31 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other coexisting autoimmune diseases
- Patients with advanced malignancy
Age
- Patients younger than 18 years of age
Who the study is looking for
- Patients diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria
- Age ≥ 18 years
- Willingness to participate in the study and provide informed consent
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.